Cargando…
Physical Activity as a New Tool to Evaluate the Response to Omalizumab and Mepolizumab in Severe Asthmatic Patients: A Pilot Study
Asthma is a chronic inflammatory airway disease, representing one of the most severe pathologies in developed countries. Based on a report of the World Health Organization (WHO), it affects about 300 million people worldwide. Few studies have analyzed the effects of daily life physical activity (PA)...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6992710/ https://www.ncbi.nlm.nih.gov/pubmed/32038267 http://dx.doi.org/10.3389/fphar.2019.01630 |
_version_ | 1783492888687017984 |
---|---|
author | Carpagnano, Giovanna Elisiana Sessa, Francesco Scioscia, Giulia Lacedonia, Donato Foschino, Maria Pia Venuti, Maria Pia Triggiani, Antonio Ivano Valenzano, Anna Resta, Onofrio Cibelli, Giuseppe Messina, Giovanni |
author_facet | Carpagnano, Giovanna Elisiana Sessa, Francesco Scioscia, Giulia Lacedonia, Donato Foschino, Maria Pia Venuti, Maria Pia Triggiani, Antonio Ivano Valenzano, Anna Resta, Onofrio Cibelli, Giuseppe Messina, Giovanni |
author_sort | Carpagnano, Giovanna Elisiana |
collection | PubMed |
description | Asthma is a chronic inflammatory airway disease, representing one of the most severe pathologies in developed countries. Based on a report of the World Health Organization (WHO), it affects about 300 million people worldwide. Few studies have analyzed the effects of daily life physical activity (PA) levels in patients with asthma: moreover, little research has been carried out on PA levels in patients suffering from severe asthma (SA). This study aimed to investigate the PA levels in two groups of patients suffering from SA; in particular, this study analyzed the changes that occur in patients treated with biologic therapy (BT group) and patients who underwent traditional treatment (TT group) over 6 months. Moreover, this study represents a pilot study because, to the best of our knowledge, it is the first investigation that analyzed if the kind of biologic drug (omalizumab or mepolizumab) can produce differences in the PA levels of SA patients. Fifty SA patients were enrolled and PA parameters were monitored for 6 months. Subjects were divided into two treatment groups: TT (20 patients) and BT (30 patients), the BT group was further subdivided according to the drugs used (15, omalizumab; 15, mepolizumab). During drug treatment, all subjects improved their PA levels: indeed, considering the intragroup variation, the PA levels were significantly higher comparing the T6 levels to baseline (T0, p < 0.01). Considering the intragroup variation, it is very interesting to note that biologic therapy improved PA levels compared to the effects of traditional therapy; while at T0 there were no significant differences in the steps per day (SPD) values between the two groups (T0, p = 0.85), the differences become statistically significant at T1, T3, and T6 (T1, p = 0.019; T3, p = 3.48x10(−6); T6, p = 4.78x10(−10)). As expected, the same differences were reported analyzing the energy expenditure data. In conclusion, this pilot study reports a positive relationship between biologic drug therapy and PA patterns, even if further studies are needed. |
format | Online Article Text |
id | pubmed-6992710 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-69927102020-02-07 Physical Activity as a New Tool to Evaluate the Response to Omalizumab and Mepolizumab in Severe Asthmatic Patients: A Pilot Study Carpagnano, Giovanna Elisiana Sessa, Francesco Scioscia, Giulia Lacedonia, Donato Foschino, Maria Pia Venuti, Maria Pia Triggiani, Antonio Ivano Valenzano, Anna Resta, Onofrio Cibelli, Giuseppe Messina, Giovanni Front Pharmacol Pharmacology Asthma is a chronic inflammatory airway disease, representing one of the most severe pathologies in developed countries. Based on a report of the World Health Organization (WHO), it affects about 300 million people worldwide. Few studies have analyzed the effects of daily life physical activity (PA) levels in patients with asthma: moreover, little research has been carried out on PA levels in patients suffering from severe asthma (SA). This study aimed to investigate the PA levels in two groups of patients suffering from SA; in particular, this study analyzed the changes that occur in patients treated with biologic therapy (BT group) and patients who underwent traditional treatment (TT group) over 6 months. Moreover, this study represents a pilot study because, to the best of our knowledge, it is the first investigation that analyzed if the kind of biologic drug (omalizumab or mepolizumab) can produce differences in the PA levels of SA patients. Fifty SA patients were enrolled and PA parameters were monitored for 6 months. Subjects were divided into two treatment groups: TT (20 patients) and BT (30 patients), the BT group was further subdivided according to the drugs used (15, omalizumab; 15, mepolizumab). During drug treatment, all subjects improved their PA levels: indeed, considering the intragroup variation, the PA levels were significantly higher comparing the T6 levels to baseline (T0, p < 0.01). Considering the intragroup variation, it is very interesting to note that biologic therapy improved PA levels compared to the effects of traditional therapy; while at T0 there were no significant differences in the steps per day (SPD) values between the two groups (T0, p = 0.85), the differences become statistically significant at T1, T3, and T6 (T1, p = 0.019; T3, p = 3.48x10(−6); T6, p = 4.78x10(−10)). As expected, the same differences were reported analyzing the energy expenditure data. In conclusion, this pilot study reports a positive relationship between biologic drug therapy and PA patterns, even if further studies are needed. Frontiers Media S.A. 2020-01-24 /pmc/articles/PMC6992710/ /pubmed/32038267 http://dx.doi.org/10.3389/fphar.2019.01630 Text en Copyright © 2020 Carpagnano, Sessa, Scioscia, Lacedonia, Foschino, Venuti, Triggiani, Valenzano, Resta, Cibelli and Messina http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Carpagnano, Giovanna Elisiana Sessa, Francesco Scioscia, Giulia Lacedonia, Donato Foschino, Maria Pia Venuti, Maria Pia Triggiani, Antonio Ivano Valenzano, Anna Resta, Onofrio Cibelli, Giuseppe Messina, Giovanni Physical Activity as a New Tool to Evaluate the Response to Omalizumab and Mepolizumab in Severe Asthmatic Patients: A Pilot Study |
title | Physical Activity as a New Tool to Evaluate the Response to Omalizumab and Mepolizumab in Severe Asthmatic Patients: A Pilot Study |
title_full | Physical Activity as a New Tool to Evaluate the Response to Omalizumab and Mepolizumab in Severe Asthmatic Patients: A Pilot Study |
title_fullStr | Physical Activity as a New Tool to Evaluate the Response to Omalizumab and Mepolizumab in Severe Asthmatic Patients: A Pilot Study |
title_full_unstemmed | Physical Activity as a New Tool to Evaluate the Response to Omalizumab and Mepolizumab in Severe Asthmatic Patients: A Pilot Study |
title_short | Physical Activity as a New Tool to Evaluate the Response to Omalizumab and Mepolizumab in Severe Asthmatic Patients: A Pilot Study |
title_sort | physical activity as a new tool to evaluate the response to omalizumab and mepolizumab in severe asthmatic patients: a pilot study |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6992710/ https://www.ncbi.nlm.nih.gov/pubmed/32038267 http://dx.doi.org/10.3389/fphar.2019.01630 |
work_keys_str_mv | AT carpagnanogiovannaelisiana physicalactivityasanewtooltoevaluatetheresponsetoomalizumabandmepolizumabinsevereasthmaticpatientsapilotstudy AT sessafrancesco physicalactivityasanewtooltoevaluatetheresponsetoomalizumabandmepolizumabinsevereasthmaticpatientsapilotstudy AT sciosciagiulia physicalactivityasanewtooltoevaluatetheresponsetoomalizumabandmepolizumabinsevereasthmaticpatientsapilotstudy AT lacedoniadonato physicalactivityasanewtooltoevaluatetheresponsetoomalizumabandmepolizumabinsevereasthmaticpatientsapilotstudy AT foschinomariapia physicalactivityasanewtooltoevaluatetheresponsetoomalizumabandmepolizumabinsevereasthmaticpatientsapilotstudy AT venutimariapia physicalactivityasanewtooltoevaluatetheresponsetoomalizumabandmepolizumabinsevereasthmaticpatientsapilotstudy AT triggianiantonioivano physicalactivityasanewtooltoevaluatetheresponsetoomalizumabandmepolizumabinsevereasthmaticpatientsapilotstudy AT valenzanoanna physicalactivityasanewtooltoevaluatetheresponsetoomalizumabandmepolizumabinsevereasthmaticpatientsapilotstudy AT restaonofrio physicalactivityasanewtooltoevaluatetheresponsetoomalizumabandmepolizumabinsevereasthmaticpatientsapilotstudy AT cibelligiuseppe physicalactivityasanewtooltoevaluatetheresponsetoomalizumabandmepolizumabinsevereasthmaticpatientsapilotstudy AT messinagiovanni physicalactivityasanewtooltoevaluatetheresponsetoomalizumabandmepolizumabinsevereasthmaticpatientsapilotstudy |